PMID- 14593367
OWN - NLM
STAT- MEDLINE
DCOM- 20040414
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 43
IP  - 9
DP  - 2003
TI  - [Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis 
      during and after treatment with unfractionated heparin and enoxaparin].
PG  - 28-40
AB  - AIM: To compare changes of parameters of hemostasis in patients with non-ST 
      elevation acute coronary syndrome (NSTEACS) during and after treatment with 
      unfractionated heparin (UFH) and low molecular weight heparin (LMWH) enoxaparin. 
      MATERIAL: Control groups of 2 randomized studies of effects of thienopyridines in 
      NSTEACS with similar inclusion criteria. METHODS: In patients (n=18) of study one 
      UFH was infused intravenously for 54.2+/-22.3 h, in patients of study two 
      subcutaneous enoxaparin 1 mg/kg b.i.d. was used for 76.2+/-28.3 h. Levels of 
      D-dimer (DD), thrombin-antithrombin complex (TAT), prothrombin fragment 1+2 
      (F1+2), von Willebrand factor (vWF), fibrinogen, tissue plasminogen activator 
      (TPA) and activity of its inhibitor (PAI), soon after start of treatment with 
      heparins and in 1, 3, 7 and 14 days. RESULTS AND CONCLUSION: Short term lowering 
      of DD and TAT levels occurred during UFH infusion apparently reflecting primary 
      antithrombin action of UFH. During LMWH use DD level remained unchanged however 
      its lowering was observed after cessation of LMWH (on days 7 and 14). The use of 
      LMWH was not associated with increases of thrombinemia (TAT), thrombin generation 
      (F1+2), and fibrinogen which were registered after end of UFH infusion (days 3, 7 
      and 14). Neither UFH nor LMWH prevented acute phase vWF elevation. The use of 
      both heparins was associated with changes that could be interpreted as 
      profibrinolytic. In LMWH treated patients these changes (elevations of TPA level) 
      became manifested early (on day 3) and were short lived while in UFH treated 
      patients they appeared later (on day 7) and were prolonged (as lowered PAI 
      activity on day 14).
FAU - Averkov, O V
AU  - Averkov OV
AD  - Research Institute for Physicochemical Medicine, ul. Malaya Pirogovskaya 1a, 
      119828 Moscow, Russia.
FAU - Slavina, N N
AU  - Slavina NN
FAU - Dobrovol'skii, A B
AU  - Dobrovol'skii AB
FAU - Gratsianskii, N A
AU  - Gratsianskii NA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Ostryi koronarnyi sindrom bez stoikikh pod"emov segmenta ST: izmeneniia 
      pokazatelei sistemy gemostaza vo vremia i posle lecheniia nefraktsionirovannym 
      geparinom i enoksaparinom.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Coronary Disease/*blood/drug therapy
MH  - Enoxaparin/administration & dosage/pharmacology/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology/therapeutic use
MH  - Hemostasis/*drug effects
MH  - Heparin/administration & dosage/*pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Syndrome
EDAT- 2003/11/01 05:00
MHDA- 2004/04/15 05:00
CRDT- 2003/11/01 05:00
PHST- 2003/11/01 05:00 [pubmed]
PHST- 2004/04/15 05:00 [medline]
PHST- 2003/11/01 05:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2003;43(9):28-40.